Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Currently, there are no available approaches to cure or slow down the progression of Alzheimer’s disease (AD), which is characterized by the accumulation of extracellular amyloid-β (Aβ) deposits and intraneuronal tangles composed of hyperphosphorylated tau. β2 adrenergic receptors (β2ARs) are expressed throughout the cortex and hippocampus and play a key role in cognitive functions. Alterations in the function of these receptors have been linked to Alzheimer’s disease; however these data remain controversial as apparent contradicting reports have been published. Given the current demographics of growing elderly population and the high likelihood of concurrent beta-blocker use for other chronic conditions, more studies into the role of this receptor in AD animal models are needed. Here we show that administration of ICI 118,551, a selective β2AR antagonist, exacerbates cognitive deficits in a mouse model of AD, the 3xTg-AD mice. Neuropathologically, ICI 118,551 increased Aβ levels and Aβ plaque burden. Concomitantly, ICI 118,551-treated 3xTg-AD mice showed an increase in tau phosphorylation and accumulation. Mechanistically, these changes were linked to an increase in amyloidogenic APP processing. These results suggest that under the conditions used here, selective pharmacological inhibition of β2ARs has detrimental effects on AD-like pathology in mice. Overall, these studies strengthen the notion that the link between β2ARs and AD is likely highly complex and suggest caution in generalizing the beneficial effects of beta-blockers on AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The novel object recognition memory: neurobiology, test procedure, and its modifications
Antunes, M., & Biala, G. (2012) · Cognitive Processing · doi:10.1007/s10339-011-0430-z · Cited by 2,390 · cited 1×
“The former is a spatial task mainly dependent on the hippocampus, while the latter relies on natural mouse behavior to explore a novel object (Antunes and Biala, 2012).”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Hock, C., Heese, K., Hulette, C., Rosenberg, C., & Otten, U. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.846 · Cited by 523
Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity.
Cowansage, K., LeDoux, J., & Monfils, M.-H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010012 · Cited by 372
Caccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362
Self-citationWalling, S. G., & Harley, C. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4426-03.2004 · Cited by 117 · cited 2×
“Indeed, β2ARs activation promotes various forms of long-term potentiation (LTP) (Connor, et al., 2011; Gelinas and Nguyen, 2005; Lin, et al., 2003; Qian, et al., 2012; Thomas, et al., 1996; Walling and Harley, 2004).”
BackgroundAntihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3
Cited by
Wang, C., Ward, M. E., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.019 · Cited by 400
“In agreementwith our findings, the selective b2-AR antagonist ICI 118,551 increased tau phosphorylation and accumulation in an AD mouse model (Branca et al., 2014).”
BackgroundLacampagne, A., Liu, X., Reiken, S., Bussiere, R., Meli, A. C., Lauritzen, I., Teich, A. F., Zalk, R., Saint, N., Arancio, O., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1733-7 · Cited by 181
Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer’s disease
Branca, C., Ferreira, E., Nguyen, T.-V., Doyle, K., Caccamo, A., & Oddo, S. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx361 · Cited by 139
Self-citationLiu, S., Xiu, J., Zhu, C., Meng, K., Li, C., Han, R., Du, T., Li, L., Xu, L., Liu, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27044-7 · Cited by 118
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“On the other side, the administration of ICI, a selective β2AR antagonist, enhanced neuropathological changes, such as increased Aβ plaque burden, as well as accumulation of phosphorylated Tau in a mouse model of AD [145].”
Background
Metadata
- Authors
- Branca, C., Wisely, E. V., Hartman, L. K., Caccamo, A., & Oddo, S.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 35
- Issue
- 12
- Pages
- 2726-2735
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2069454756
- Cited by
- 63
- References
- 7
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2014.06.011
- The paper
- Branca, C., Wisely, E. V., Hartman, L. K., Caccamo, A., & Oddo, S. (2014). Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2014.06.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.